Laduviglusib
| Catalog Number | Pack Size | List Price* | Promo Price* | Quantity | |
|---|---|---|---|---|---|
| HY-10182-1MG | 1mg | 52,00 | 33,80 | Add | |
| HY-10182-5MG | 5 mg | 109,00 | 70,90 | Add | |
| HY-10182-1ML | 10mM/1mL | 119,00 | 77,40 | Add | |
| HY-10182-10MG | 10 mg | 158,00 | 102,70 | Add | |
| HY-10182-50MG | 50 mg | 445,00 | 289,30 | Add | |
| HY-10182-100MG | 100 mg | 700,00 | 455,00 | Add | |
| HY-10182-200MG | 200 mg | 1'184,00 | 769,60 | Add | |
| HY-10182-S-1ST | Sample | Inquire |
* CHF, excl. 8.1% VAT and shipping costs
Product Description
Promotion runs until 31.12.2024Year-End Promotion : 35% discount on the entire MedChem Express portfolio
CHIR-99021; CT99021
Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy[1][2][3].
| Category | Biochemicals |
| Supplier | MedChem Express |
| Regulatory Status | RUO |
| Research Field | Cancer; Metabolic Disease |
| Format | Solubility: DMSO : 16.67 mg/mL (ultrasonic) |
| Grade | Clinical information: No Development Reported |
| Purity | 99.76% |
| Molecular Formula | C22H18Cl2N8 |
| Molecular Weight | 465.34 |
| CAS-Number | 252917-06-9 |
| Storage Conditions | -20°C, 3 years; 4°C, 2 years (Powder) |
| Tech. Data Sheet | View datasheet |
| Link To Supplier | http://www.medchemexpress.com |
| Shipping Details | Room Temperature |
| Material Safety Data Sheet | Download PDF |
